M&As this week: Duran Group, Catalent Pharma Solutions

15 September 2016 (Last Updated September 15th, 2016 18:30)

Duran Group has entered an agreement to acquire Kimble Chase Life Sciences & Research Products from Gerresheimer for a purchase consideration of $131m.

Duran Group has entered an agreement to acquire Kimble Chase Life Sciences & Research Products from Gerresheimer for a purchase consideration of $131m.

The acquisition is expected to be completed by November and will enable the acquirer to expand its presence in life sciences and research field, as well as services in the US.

Catalent subsidiary Catalent Pharma Solutions plans to expand its drug development services and spray-drying technology through the acquisition of Pharmatek laboratories.

The acquirer is an advanced drug delivery technologies and development solutions provider, whereas the target is a drug development and clinical manufacturing company.